Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESSO 45 | Omitting axillary surgery after complete response to neoadjuvant therapy

Antonio Esgueva, MD, PhD, University Hospital of Navarra, Madrid, Spain, comments on emerging evidence on whether axillary surgery can be safely omitted in node-negative patients with complete response to neoadjuvant therapy. Data from patients in the EUSOMA database across European breast units demonstrated that residual axillary disease occurs in only 1–2% of triple-negative and HER2-positive patients with complete breast response, aligning with findings from trials such as EUBREAST-01(NCT04101851), ASLAN (NCT04993625), and OPTIMIST (NCT05505357). Real-world patients meeting trial inclusion criteria could benefit from reduced surgical intervention, resulting in fewer complications such as arm swelling and improved quality of life, provided they receive care from specialized multidisciplinary breast teams. This interview took place at the 2026 European Society of Surgical Oncology (ESSO) Annual Meeting in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Well, traditionally, patients who were node-negative at diagnosis still have a sentinel node biopsy after neoadjuvant therapy to check the axillary. Now, we are more and more trials testing whether we can safely skip that surgery in these patients. For example, we have the EURBREAST-01 in Europe, or the ASLAN and the OPTIMIST trials in Korea. They may include triple-negative and HER2-POSITIVE tumours that respond completely in the breast...

Well, traditionally, patients who were node-negative at diagnosis still have a sentinel node biopsy after neoadjuvant therapy to check the axillary. Now, we are more and more trials testing whether we can safely skip that surgery in these patients. For example, we have the EURBREAST-01 in Europe, or the ASLAN and the OPTIMIST trials in Korea. They may include triple-negative and HER2-POSITIVE tumours that respond completely in the breast. We wanted to know whether the inclusion criteria of these trials apply to real-world patients. So we looked at almost 6 ,000 patients from the USOMA database. is an European network of hospitals with 35 specialised breast units that meet strict quality standards. So these aren’t data from one centre or from a trial population. They reflect everyday practice in high-quality breast units across Europe. That makes the results very relevant to routine care. the results were consistent. With what the trials have shown so far. In triple-negative and HER2-POSITIVE patients with a complete response in the breast, residual disease in the axilla was very, very low, between 1 % and 2%. In other words, if we have skipped axillary surgery in these women, disease would have gone undetected in just one or two of every hundred. still waiting for the oncological results of these trials. But our data show that, in the real world, the patients who could avoid axillary surgery do meet the inclusion criteria of these studies. So, once the trial results arrive, they can be applied directly to patients in everyday practice and those patients will benefit. That means less surgery, fewer side effects such as arm swelling and better quality of life. That we move into a safer, less aggressive surgery. Near-juvenile therapy doesn’t compromise breast conservation and for some women, axillary surgery may soon be avoidable. The key is to be treated by a specialized multidisciplinary breast team.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.